logo
Plus   Neg
Share
Email

Lipocine Receives Complete Response Letter From FDA For TLANDO - Quick Facts

Lipocine Inc. (LPCN) has received a Complete Response Letter or CRL from the FDA regarding the company's New Drug Application for TLANDO, an oral testosterone product candidate. The FDA has stated that the efficacy trial did not meet the three secondary endpoints for maximal testosterone concentrations.

"We are disappointed by the FDA's decision and intend to request a meeting with the FDA as soon as possible to discuss a potential path forward for the approval of TLANDO," said Mahesh Patel, CEO of Lipocine.

Shares of Lipocine Inc. were down nearly 34% in pre-market trade on Monday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Video streaming giant Netflix announced plans to significantly increase its investment in France with 20 new French productions, and partnerships with leading French creative institutions. Netflix on Monday opened its new headquarters in France, located in the heart of Paris. Netflix France currently... Toyota Motor Corp. has invested $394 million in U.S. electric air-taxi startup Joby Aviation as lead investor in the recent $590 million Series C financing. Toyota said it is continuing to leverage emerging technologies to provide "Mobility for All" as the lead investor as part of its transformation into a mobility company. As the world is facing severe consequences of increasing carbon emissions, Microsoft has announced various plans to tackle the issue. The company aims to reduce its own carbon emissions by more than half, and to be carbon negative by 2030. This means the company will remove more carbon than it emits each year. The company further announced a new $1 billion Climate Innovation Fund.
Follow RTT
>